Predicted effect of incidental pulmonary nodule findings on Non-Small Cell Lung Cancer mortality.

IF 21 1区 医学 Q1 ONCOLOGY Journal of Thoracic Oncology Pub Date : 2024-11-12 DOI:10.1016/j.jtho.2024.11.009
S Tuminello, R Flores, M Untalan, T Ivic-Pavlicic, C I Henschke, R Yip, D F Yankelevitz, E Taioli
{"title":"Predicted effect of incidental pulmonary nodule findings on Non-Small Cell Lung Cancer mortality.","authors":"S Tuminello, R Flores, M Untalan, T Ivic-Pavlicic, C I Henschke, R Yip, D F Yankelevitz, E Taioli","doi":"10.1016/j.jtho.2024.11.009","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Despite the reduction in mortality shown by Low dose computer tomography (LDCT) lung cancer screening, the uptake is still low. Patients undergo chest imaging for several other medical reasons, and this is a unique opportunity to detect lung nodules.</p><p><strong>Methods: </strong>In a cohort of NSCLC patients from the Surveillance, Epidemiology and End Results (SEER)-Medicare linked data, tumor size at previous imaging was calculated as: VDT = [(T<sub>2</sub>-T<sub>1</sub>)·ln2]/ln(V<sub>2</sub>/V<sub>1</sub>), solving for diameter of V<sub>1</sub>. V<sub>1</sub> and V<sub>2</sub> are tumor volume at times T<sub>1</sub> (previous imaging) and T<sub>2</sub> (diagnostic procedure) according to three different growth models. 10-year lung cancer-specific mortality was calculated as: lung cancer survival rate = (-0.0098 × maximum tumor diameter) + 1.</p><p><strong>Results: </strong>1,007 patients who had a chest imaging performed up to one year prior to lung cancer diagnosis. The median size of the tumor at diagnosis was 25 mm, the predicted median tumor size at previous imaging was 12.16 mm, 17.3 mm, and 20.42 mm under the fast, medium and slow growth model. Under the fast growth model, a detection of the nodule at previous imaging would have yield a decrease in mortality of 7.79%; the corresponding values for the medium growth model is 4.5%, for the slow growth model 2.45%.</p><p><strong>Conclusions: </strong>Identifying malignant lung nodules in imaging performed for other clinical reasons can help decreasing the burden of NSCLC, especially for non-LDCT eligible patients and the medically vulnerable. We show here that clinical benefits, especially among patients with aggressive disease, can be considerable.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtho.2024.11.009","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Despite the reduction in mortality shown by Low dose computer tomography (LDCT) lung cancer screening, the uptake is still low. Patients undergo chest imaging for several other medical reasons, and this is a unique opportunity to detect lung nodules.

Methods: In a cohort of NSCLC patients from the Surveillance, Epidemiology and End Results (SEER)-Medicare linked data, tumor size at previous imaging was calculated as: VDT = [(T2-T1)·ln2]/ln(V2/V1), solving for diameter of V1. V1 and V2 are tumor volume at times T1 (previous imaging) and T2 (diagnostic procedure) according to three different growth models. 10-year lung cancer-specific mortality was calculated as: lung cancer survival rate = (-0.0098 × maximum tumor diameter) + 1.

Results: 1,007 patients who had a chest imaging performed up to one year prior to lung cancer diagnosis. The median size of the tumor at diagnosis was 25 mm, the predicted median tumor size at previous imaging was 12.16 mm, 17.3 mm, and 20.42 mm under the fast, medium and slow growth model. Under the fast growth model, a detection of the nodule at previous imaging would have yield a decrease in mortality of 7.79%; the corresponding values for the medium growth model is 4.5%, for the slow growth model 2.45%.

Conclusions: Identifying malignant lung nodules in imaging performed for other clinical reasons can help decreasing the burden of NSCLC, especially for non-LDCT eligible patients and the medically vulnerable. We show here that clinical benefits, especially among patients with aggressive disease, can be considerable.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
偶然发现肺结节对非小细胞肺癌死亡率的预测影响。
简介尽管低剂量计算机断层扫描(LDCT)肺癌筛查降低了死亡率,但接受率仍然很低。患者接受胸部成像检查还有其他一些医疗原因,而这正是检测肺结节的独特机会:在监测、流行病学和终末结果(SEER)--医疗保险链接数据中的 NSCLC 患者队列中,上次成像时肿瘤大小的计算方法为VDT = [(T2-T1)-ln2]/ln(V2/V1),求解 V1 的直径。根据三种不同的生长模型,V1 和 V2 分别为 T1(上次成像)和 T2(诊断过程)时的肿瘤体积。10 年肺癌特异性死亡率的计算公式为:肺癌生存率 = (-0.0098 × 最大肿瘤直径) + 1.结果:1007 名患者在确诊肺癌前一年进行了胸部成像检查。确诊时肿瘤的中位尺寸为 25 毫米,在快速、中速和慢速生长模型下,预测的上次成像时肿瘤的中位尺寸分别为 12.16 毫米、17.3 毫米和 20.42 毫米。在快速生长模型下,如果在之前的成像中发现结节,死亡率将降低 7.79%;中速生长模型的相应数值为 4.5%,慢速生长模型为 2.45%:在因其他临床原因而进行的成像中识别恶性肺结节有助于减轻 NSCLC 的负担,尤其是对于不符合LDCT 条件的患者和医学上的弱势群体。我们在此表明,临床获益,尤其是侵袭性疾病患者的获益,是相当可观的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Thoracic Oncology
Journal of Thoracic Oncology 医学-呼吸系统
CiteScore
36.00
自引率
3.90%
发文量
1406
审稿时长
13 days
期刊介绍: Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.
期刊最新文献
PCI for Patients with Small Cell Lung Cancer: A New Perspective in the Immunotherapy Era. Safety, efficacy and biomarker analysis of deulorlatinib (TGRX-326) in ALK-positive non-small-cell lung cancer: a multicentre, open-label, phase 1/1b trial. Predicted effect of incidental pulmonary nodule findings on Non-Small Cell Lung Cancer mortality. DSTYK Inhibition Sensitizes Non-Small Cell Lung Cancer To Taxane-Based Chemotherapy. Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression ≥25%: Results from the Randomized Phase 3 PEARL Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1